Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
FRAX™ and the assessment of fracture probability in men and women from the UK
2008 Standout
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
2004
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Vascularized and functional human liver from an iPSC-derived organ bud transplant
2013 StandoutNature
Comparative effects of cilostazol and other therapies for intermittent claudication
2001
British Hypertension Society guidelines for hypertension management 1999: summary
1999
Global burden of hypertension: analysis of worldwide data
2005 Standout
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement
2003
Hypertension in the Very Elderly Trial (HYVET)
2001
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Drug-Induced Acute Pancreatitis
1989
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production
2002
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000
2003 Standout
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
2004 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Global risk of cardiovascular disease
2003
Intervention thresholds for osteoporosis
2002
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
1991 Standout
An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas
2003
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
The development of allergic inflammation
2008 StandoutNature
Diabetes and Atherosclerosis
2002 Standout
Inter-arm differences in blood pressure: when are they clinically significant?
2002
A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: Secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial
2006
Effect of the Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene on Response to Angiotensin-Converting Enzyme Inhibitors in Patients with Heart Failure
1998
Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy
1992
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Rationale for Fixed-Dose Combinations in the Treatment of Hypertension
2002
Acute Pancreatitis
1994 Standout
Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women
2009 Standout
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
1997 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
2004 Standout
Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood Pressure lowering Drugs
2001
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
2008 Standout
Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates
2004
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)
2004
Hypokalemic and ECG Sequelae of Combined Beta-Agonist/Diuretic Therapy
1990
Validation of the Framingham Coronary Heart Disease Prediction Scores
2001 Standout
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
2005 Standout
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
2004
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Improved Hypertension Management and Control
2001
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial
2005 Standout
Definition of Metabolic Syndrome
2004 Standout
Prediction of Coronary Heart Disease Using Risk Factor Categories
1998 Standout
The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension
2003
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
1989
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs
1987
Hypertension Treatment and Control in Five European Countries, Canada, and the United States
2003
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention
2004
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
2001
Statins for the primary prevention of cardiovascular disease
2013
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication
1998
Medium-Term Variability of Blood Pressure and Potential Underdiagnosis of Hypertension in Patients With Previous Transient Ischemic Attack or Minor Stroke
2006
Influence of body and arm position on blood pressure readings
2003
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
2007 Standout
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
2013 Standout
Are Infra-Inguinal Angioplasty and Surgery Comparable?
2001
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
How general practitioners perceive and grade the cardiovascular risk of their patients
2004
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
General Cardiovascular Risk Profile for Use in Primary Care
2008 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control
2002
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
Pathophysiology and clinical presentations of cough
1996
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Recommendations for Blood Pressure Measurement in Humans and Experimental Animals
2005 Standout
beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.
1991
Works of LE Ramsay being referenced
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table
1996
Guidelines for management of hypertension: report of the third working party of the British Hypertension Society
1999
Relative potency of spironolactone, triamterene and potassium chloride in thiazide‐induced hypokalaemia.
1982
Effect of dose adjustment on enalapril‐induced cough and the response to inhaled capsaicin.
1995
Quantification of side‐effects of beta‐adrenoceptor blockers using visual analogue scales.
1984
Polymorphic metabolism of beta‐adrenoceptor antagonists.
1984
Spironolactone in thiazide‐induced hypokalaemia: variable response between patients.
1981
Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.
1995
Side‐effects of beta‐adrenoceptor blocking drugs assessed by visual analogue scales.
1985
Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison.
1990
Methyldopa-induced chronic pancreatitis.
1982
Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965‐1985 [see comments]
1988
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
1984
Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?
1996
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
1985